Squarepoint
RNTX

Squarepoint’s Rein Therapeutics RNTX Stock Holding History

Squarepoint’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,758
Closed -$112K – 2907
2020
Q2 		$112K Buy
+4,758
New +$77.5K ﹤0.01% 1988
2018
Q1 		– Sell
-554
Closed -$117K – 2220
2017
Q4 		$117K Buy
+554
New +$133K ﹤0.01% 1928

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Squarepoint's RNTX Position: Q3 2020 in Review

Squarepoint sold out of Rein Therapeutics (RNTX) in Q3 2020, closing a stake of 4,758 shares — an estimated $112K sold.

Squarepoint first reported a position in RNTX in Q4 2017 and held it in 2 quarters. The position peaked at $117K in Q4 2017. 28 funds tracked by Wall St. Rank hold RNTX as of Q3 2020.

  • Squarepoint reported no remaining Rein Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Squarepoint sold 4,758 Rein Therapeutics shares in Q3 2020, an estimated $112K.
  • Squarepoint first reported a position in Rein Therapeutics in Q4 2017 and held it in 2 quarters.
  • Squarepoint's Rein Therapeutics position peaked at $117K in Q4 2017.
  • 28 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2020.

Based on Squarepoint's 13F filing for Q3 2020, filed 16 Nov 2020.